Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer

Kazuhiko Shien, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba

Research output: Contribution to journalReview article

57 Citations (Scopus)

Abstract

Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially increase the efficacy of therapy for various malignancies, including non–small cell lung cancer (NSCLC). At the same time, substantial effort has been invested in finding biomarkers predicting which patients will respond best to this immune checkpoint inhibition. PD-L1 expression in tumor cells and the tumor microenvironment, genetic alterations and mutational load in tumor cells, and pre-existing immunity and its enhancement during treatment through tumor-infiltrating immune cells have been associated with outcomes of immune checkpoint inhibition. Here, we review the reported predictive biomarkers of response to PD-1 pathway immune checkpoint inhibitors in NSCLC, mainly focusing on results obtained with clinical trials.

Original languageEnglish
Pages (from-to)79-87
Number of pages9
JournalLung Cancer
Volume99
DOIs
Publication statusPublished - Sep 1 2016
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cell Death
Biomarkers
Cellular Microenvironment
Neoplasms
Tumor Microenvironment
Tumor Burden
Immunity
Clinical Trials
Therapeutics

Keywords

  • Biomarker
  • Immune checkpoint inhibition
  • NSCLC
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer. / Shien, Kazuhiko; Papadimitrakopoulou, Vassiliki A.; Wistuba, Ignacio I.

In: Lung Cancer, Vol. 99, 01.09.2016, p. 79-87.

Research output: Contribution to journalReview article

Shien, Kazuhiko ; Papadimitrakopoulou, Vassiliki A. ; Wistuba, Ignacio I. / Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer. In: Lung Cancer. 2016 ; Vol. 99. pp. 79-87.
@article{521df76f207147fc9b483ea2ccecdb00,
title = "Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer",
abstract = "Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially increase the efficacy of therapy for various malignancies, including non–small cell lung cancer (NSCLC). At the same time, substantial effort has been invested in finding biomarkers predicting which patients will respond best to this immune checkpoint inhibition. PD-L1 expression in tumor cells and the tumor microenvironment, genetic alterations and mutational load in tumor cells, and pre-existing immunity and its enhancement during treatment through tumor-infiltrating immune cells have been associated with outcomes of immune checkpoint inhibition. Here, we review the reported predictive biomarkers of response to PD-1 pathway immune checkpoint inhibitors in NSCLC, mainly focusing on results obtained with clinical trials.",
keywords = "Biomarker, Immune checkpoint inhibition, NSCLC, PD-1, PD-L1",
author = "Kazuhiko Shien and Papadimitrakopoulou, {Vassiliki A.} and Wistuba, {Ignacio I.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.lungcan.2016.06.016",
language = "English",
volume = "99",
pages = "79--87",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer

AU - Shien, Kazuhiko

AU - Papadimitrakopoulou, Vassiliki A.

AU - Wistuba, Ignacio I.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially increase the efficacy of therapy for various malignancies, including non–small cell lung cancer (NSCLC). At the same time, substantial effort has been invested in finding biomarkers predicting which patients will respond best to this immune checkpoint inhibition. PD-L1 expression in tumor cells and the tumor microenvironment, genetic alterations and mutational load in tumor cells, and pre-existing immunity and its enhancement during treatment through tumor-infiltrating immune cells have been associated with outcomes of immune checkpoint inhibition. Here, we review the reported predictive biomarkers of response to PD-1 pathway immune checkpoint inhibitors in NSCLC, mainly focusing on results obtained with clinical trials.

AB - Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially increase the efficacy of therapy for various malignancies, including non–small cell lung cancer (NSCLC). At the same time, substantial effort has been invested in finding biomarkers predicting which patients will respond best to this immune checkpoint inhibition. PD-L1 expression in tumor cells and the tumor microenvironment, genetic alterations and mutational load in tumor cells, and pre-existing immunity and its enhancement during treatment through tumor-infiltrating immune cells have been associated with outcomes of immune checkpoint inhibition. Here, we review the reported predictive biomarkers of response to PD-1 pathway immune checkpoint inhibitors in NSCLC, mainly focusing on results obtained with clinical trials.

KW - Biomarker

KW - Immune checkpoint inhibition

KW - NSCLC

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=84977274739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977274739&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2016.06.016

DO - 10.1016/j.lungcan.2016.06.016

M3 - Review article

C2 - 27565919

AN - SCOPUS:84977274739

VL - 99

SP - 79

EP - 87

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -